Literature DB >> 16376175

High circulating levels of 7beta- and 7alpha-hydroxycholesterol and presence of apoptotic and oxidative markers in arterial lesions of normocholesterolemic atherosclerotic patients undergoing endarterectomy.

C Prunet1, J M Petit, A Ecarnot-Laubriet, A Athias, C Miguet-Alfonsi, J F Rohmer, E Steinmetz, D Néel, P Gambert, G Lizard.   

Abstract

In previous investigations, we found that 7beta-hydroxycholesterol had potent pro-apoptotic, and pro-oxidative properties. So, we asked whether the circulating level of this oxysterol was enhanced in atherosclerotic patients undergoing endarterectomy of the superficial femoral artery. To this end, 7beta-hydroxycholesterol serum concentrations were determined and compared with common lipid parameters in atherosclerotic patients, and in healthy subjects. 7alpha-hydroxycholesterol was simultaneously measured to evaluate the reliability of the method used for oxysterol analysis. On normal and atherosclerotic arterial fragments from patients, markers of oxidation (4-hydroxynonenal (4-HNE) adducts), and apoptosis (activated caspase-3; condensed/fragmented nuclei) were studied. Interestingly, high serum concentrations of 7beta- and 7alpha-hydroxycholesterol were found in normocholesterolemic atherosclerotic patients. However, in statin-treated patients, the circulating levels of 7beta- and 7alpha-hydroxycholesterol tend towards normal values. Therefore, 7beta- as well as 7alpha-hydroxycholesterol could be more appropriate markers of lipid metabolism disorders than cholesterol or LDL in normocholesterolemic patients with atherosclerosis of the lower limbs, and statins could normalize their serum concentrations. At the arterial level, apoptotic cells were mainly identified in low grade lesions and no statin effects were found on oxidation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376175     DOI: 10.1016/j.patbio.2004.11.002

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  7 in total

1.  Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease.

Authors:  Forbes D Porter; David E Scherrer; Michael H Lanier; S Joshua Langmade; Vasumathi Molugu; Sarah E Gale; Dana Olzeski; Rohini Sidhu; Dennis J Dietzen; Rao Fu; Christopher A Wassif; Nicole M Yanjanin; Steven P Marso; John House; Charles Vite; Jean E Schaffer; Daniel S Ory
Journal:  Sci Transl Med       Date:  2010-11-03       Impact factor: 17.956

Review 2.  The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.

Authors:  Erik R Nelson
Journal:  Mol Cell Endocrinol       Date:  2017-09-15       Impact factor: 4.102

3.  11β-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo.

Authors:  Tijana Mitić; Steven Shave; Nina Semjonous; Iain McNae; Diego F Cobice; Gareth G Lavery; Scott P Webster; Patrick W F Hadoke; Brian R Walker; Ruth Andrew
Journal:  Biochem Pharmacol       Date:  2013-02-13       Impact factor: 5.858

4.  Simvastatin reduces circulating oxysterol levels in men with hypercholesterolaemia.

Authors:  Irundika H K Dias; Ivana Milic; Gregory Y H Lip; Andrew Devitt; M Cristina Polidori; Helen R Griffiths
Journal:  Redox Biol       Date:  2018-02-17       Impact factor: 11.799

5.  Oncogenic roles of the cholesterol metabolite 25-hydroxycholesterol in bladder cancer.

Authors:  Chen Wang; Haowei He; Wennian Fang
Journal:  Oncol Lett       Date:  2020-03-27       Impact factor: 2.967

Review 6.  Cholesterol, Oxysterols and LXRs in Breast Cancer Pathophysiology.

Authors:  Hassan Nazih; Jean Marie Bard
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

7.  Anti-Inflammatory and Proliferative Properties of Luteolin-7-O-Glucoside.

Authors:  Alessandro De Stefano; Sabrina Caporali; Nicola Di Daniele; Valentina Rovella; Carmine Cardillo; Francesca Schinzari; Marilena Minieri; Massimo Pieri; Eleonora Candi; Sergio Bernardini; Manfredi Tesauro; Alessandro Terrinoni
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.